Division of Urology, Faculdade de Medicina do ABC, Santo André, Brazil.
Hospital Municipal da Vila Santa Catarina and Hospital Israelita Albert Einstein, São Paulo, Brazil.
JCO Glob Oncol. 2021 Sep;7:1547-1555. doi: 10.1200/GO.21.00104.
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a complex treatment. In Brazil, as in most developing countries, data are scarce, but mortality seems exceedingly high. We have created a centralization program involving a multidisciplinary clinic in a region comprising seven municipalities. The aim of this study is to evaluate the impact of a multidisciplinary clinic and a centralization-of-care program (CABEM program) on MIBC treatment in Brazil.
A total of 116 consecutive patients were evaluated. In group 1, 58 patients treated for MIBC before establishing a bladder cancer program from 2011 to 2017 were retrospectively evaluated. Group 2 represented 58 patients treated for MIBC after the implementation of the CABEM centralization program. Age, sex, staging, comorbidity indexes, mortality rates, type of treatment, and perioperative outcomes were compared.
Patients from group 2 versus 1 were older (68 64.2 years, = .02) with a higher body mass index (25.5 22.6 kg/m, = .017) and had more comorbidities according to both age-adjusted Charlson Comorbidity Index (4.2 2.8, = .0007) and Isbarn index (60.6 43.9, = .0027). Radical cystectomy (RC) was the only treatment modality for patients in group 1, whereas in group 2, there were 31 (53%) RC; three (5%) partial cystectomies; seven (12%) trimodal therapies; 13 (22%) palliative chemotherapies; and three (5%) exclusive transurethral resections of the bladder tumor. No patient in group 1 received neoadjuvant chemotherapy, whereas it was offered to 69% of patients treated with RC. Ninety-day mortality rates were 34.5% versus 5% for groups 1 versus 2 ( < .002). One-year mortality was also lower in group 2.
Our data support that a centralization program, a structured bladder clinic associated with protocols, a multidisciplinary team, and inclusion of chemotherapy and radiotherapy treatments can pleasingly improve outcomes for patients with MIBC.
肌层浸润性膀胱癌(MIBC)是一种侵袭性疾病,治疗复杂。在巴西,与大多数发展中国家一样,数据匮乏,但死亡率似乎极高。我们创建了一个涉及七个城市的多学科临床中心的集中化项目。本研究旨在评估多学科临床和集中治疗计划(CABEM 计划)对巴西 MIBC 治疗的影响。
共评估了 116 例连续患者。在第 1 组中,回顾性评估了 2011 年至 2017 年建立膀胱癌项目之前治疗 MIBC 的 58 例患者。第 2 组代表了 58 例接受 CABEM 集中化计划后治疗 MIBC 的患者。比较了年龄、性别、分期、合并症指数、死亡率、治疗类型和围手术期结果。
第 2 组患者比第 1 组患者年龄更大(68 64.2 岁, =.02),体重指数更高(25.5 22.6 kg/m, =.017),且根据年龄调整后的 Charlson 合并症指数(4.2 2.8, =.0007)和 Isbarn 指数(60.6 43.9, =.0027)的合并症更多。第 1 组患者仅接受根治性膀胱切除术(RC)治疗,而第 2 组中,有 31 例(53%)接受 RC;3 例(5%)接受部分膀胱切除术;7 例(12%)接受三联疗法;13 例(22%)接受姑息性化疗;3 例(5%)仅接受膀胱肿瘤经尿道切除术。第 1 组中无患者接受新辅助化疗,而接受 RC 治疗的患者中有 69%接受了新辅助化疗。第 1 组和第 2 组的 90 天死亡率分别为 34.5%和 5%( <.002)。第 2 组的 1 年死亡率也较低。
我们的数据支持集中化计划、与方案相关的结构化膀胱临床、多学科团队以及纳入化疗和放疗治疗可以显著改善 MIBC 患者的结局。